Rigel Pharma appoints two senior executives
Dr. Masuda most recently held the title of Senior Vice President, Immunology at Rigel. He has worked on and led numerous drug discovery projects in inflammatory and allergic diseases.
His work has resulted in moving several product candidates into clinical development; various corporate partnerships; 57 publications; and 49 U.S. issued patents.
Prior to joining Rigel, Dr. Masuda spent seven years at DNAX Research Institute of Molecular and Cellular Biology in cytokine biology.
He received a B.S. in biochemistry from University of California, Riverside and a Ph.D. in molecular genetics from Hiroshima University, Japan.
Mr. Lasaga returns to Rigel from his role as Vice President, Business Development and Alliance Management at Galena Biopharma where he was responsible for managing corporate and business development strategy and activities.
From 2010 until 2014, he was Director, and later named Senior Director, Business Development at Nektar Therapeutics.
Mr. Lasaga began his career at Rigel working in research before moving into business development, most recently as Associate Director.
Mr. Lasaga graduated from San Jose State University with a B.S. in Molecular Biology and earned his M.B.A. in Marketing from San Francisco State University. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST